IDO1 and irritable bowel syndrome: During active phases of the disease patients with IBD exhibit decreased tryptophan levels mainly as a result of an inflammation-induced upregulation of indoleamine 2,3-dioxygenase (IDO1), which is a rate-limiting enzyme catalyzing tryptophan to kynurenine and shifting tryptophan metabolism to the kynurenine pathway [98].